Dublin, April 22, 2022 (GLOBE NEWSWIRE) -- The "Global Insulin Syringes Market Size, Share & Industry Trends Analysis Report By Disease (Type 2 Diabetes and Type 1 Diabetes), By Syringe Size, By End User, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering. The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period. The world's aging population and expanding number of diabetes patients are two significant reasons driving the market's growth. Furthermore, rising obesity rates and individuals adopting unhealthy lifestyles contribute to market development. The growth in healthcare costs is a significant element driving demand for insulin syringes. Companies may now offer their items online as a result of increased digitization. Insulin syringes are being sold online by a growing number of firms. Diabetes affects people in both urban and rural places across the world, with 64 percent of cases occurring in cities and 36% in rural areas. Consumers from emerging countries account for the majority of the market. The rise in diabetes cases is a big motivator for the producers. Companies may take advantage of these distinct market characteristics by establishing a strong retail distribution infrastructure. Diabetes is predicted to cost USD 286 billion in direct healthcare expenditures per year for adults aged 20 to 79 over the world. COVID-19 Impact Analysis The World Health Organization (WHO) designated the COVID-19 pandemic a public health emergency of worldwide significance on January 30, 2020. COVID-19 has impacted over 210 nations throughout the world. Governments throughout the world have issued country-wide lockdowns and social distancing measures in response to the COVID-19 epidemic, in order to prevent the healthcare system from collapsing. Medical treatments and elective operations were also subjected to restrictions and bans by governments. These limitations continue to hinder the growth of many businesses, and the outbreak's immediate impact differs by industry. Market Growth Factors:
Availability of low-cost insulin and rising R&D spending The introduction of generic insulin and the rapidly expanding demand for innovative insulin in the regulation of blood sugar levels across both type 1 and type 2 diabetes are expected to drive the growth of the insulin sector in the market during the projected period. Lispro, a generic version of rapid-acting Humalog insulin, was announced in March 2019 by Eli Lilly and Company. It will be accessible at much more affordable prices for diabetic patients. Reduce the dependency on medical professionals Insulin is often used by diabetic people since it is essential to be taken on a daily basis based on the type of diabetes. As a result, going to the doctor every day to get insulin injections can be costly and time consuming. People must carve out time from their busy schedules. People are searching for easier choices as their schedules get more hectic, therefore they utilise insulin syringes. When insulin syringes were utilised, patients reported a better overall injection experience. The size of insulin syringes varies depending on the amount of insulin used. Marketing Restraining Factor:
High prices of insulin syringes Lower-income nations are facing an unsustainable financial burden as the global market shifts away from human insulin, that can be generated at a low cost, and toward more expensive analogues (synthetic insulins). Human insulin is equally effective as analogues in most cases, however analogues are at least 1.5 times more expensive, and in certain cases 3 times more expensive; three multinational businesses dominate more than 90% of the insulin market, limiting the potential for smaller companies to compete for sales. Insulin expenses in the United States have been steadily growing for years, forcing diabetics and their families to make difficult decisions. Disease Outlook On the basis of Disease, the insulin syringe market is segmented into Type 1 Diabetes and Type 2 Diabetes. Type 2 Diabetes is expected to account for the largest revenue share in the Insulin Syringes Market by 2020. This is due to an increase in the global prevalence of type-2 diabetes. According to the World Health Organization, around 462 million people worldwide have type 2 diabetes in 2019, accounting for 6.28 percent of the global population. Syringe Size Outlook The insulin syringe market is classified into three categories based on syringe size: 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml), and Others. In the year 2020, the 1ml syringe size has taken up the majority of sales. These syringes have a 2-unit graduation and are suited for dosages of more than 50 units. For an adult who requires a considerable dose of insulin, a 1 mL syringe could be the best option. End User Outlook On the basis on End User, the insulin syringe market is categorized into Hospitals & Clinics, Homecare Settings, and Others. Due to the rising incidence of chronic illnesses like diabetes and obesity among the population, the hospital & clinics segment earned the biggest revenue share in the insulin syringes market. Furthermore, the rapidly growing geriatric population is a major driver of the insulin syringes industry. According to the American Diabetes Association, around 34.2 million individuals were diagnosed with diabetes in 2019, with 14.3 million of those over 65 years old suffering from the disease. Regional Outlook Based on region, the insulin syringes market is studied across North America, Europe, Asia Pacific, and LAMEA. North America is expected to be the leading region in the Insulin Syringes Market by 2020, with the largest revenue share. This is mostly attributable to the region's sophisticated technology and new product releases by major market participants. Diabetes is the seventh largest cause of mortality in the United States, according to the Centers for Disease Control and Prevention (CDC). Diabetes is no longer confined to wealthy countries, but is increasingly affecting low- and middle-income countries. Recent Strategy Deployed in Insulin Syringes Market
Oct-2021: Eli Lilly formed a partnership with Cipla, the Indian multinational pharmaceutical company. This partnership focused on strengthening the outreach of Lilly's Diabetes products, Trulicity, and Humalog in India. Additionally, Lilly is expected to transfer all its rights with regulatory approvals to Cipla for promoting, distributing, and selling the Trulicity & Humalog in India.
Aug-2021: Eli Lilly received approval from the US FDA approval for Lyumjev, rapid-acting insulin. Through this approval, the continuous 100 units/mL subcutaneous insulin infusion (CSII) with an insulin pump is expected to help adults with type 1 and type 2 diabetes to regulate glycemic levels.
Jul-2021: Biocon Biologics and Viatris received FDA approval for Semglee, the first interchangeable biosimilar product. Through this approval, pharmacy counters are expected to witness, Lantus substitution Semglee, introduced in the market by the end of this year.
Hindustan Syringes & Medical Devices Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/umrxdf
Investors are trying to make sense of the markets, in face of conflicting signals. Year-to-date, we’re facing deep losses – but more recently, a sharp rally despite this week’s confirmation that we’re in a recession. Government data released on Thursday showed a 0.9% GDP contraction in Q2, which came on the heels of a 1.6% contraction in Q1. That’s two quarters in a row, the definition of a recession. Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, reminds us the ‘conventional wis
Looking to buy the dip? Start here.
When his green credentials were challenged by a young activist on the election trail, Joe Biden had a simple answer.
When Elon Musk decided to terminate his $44 billion deal to purchase Twitter the social-media company sued in the Delaware Court of Chancery. Twitter is suing for “specific performance,” a rare remedy that would require Musk to complete the merger. Unfortunately for Twitter, it isn’t Elon Musk Inc. but Elon Musk the individual who offered to buy the company.
We don’t advocate for theft. But stealing these strategies is a victimless crime.
(Bloomberg) -- Dennis Levitt got his first Tesla, a blue Model S, in 2013, and loved it. “It was so much better than any car I've ever driven,” the 73-year-old self-storage company executive says.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekShock July Stock Rally Was a Monster the Fed May Regret SeeingMeet the Russian Architect of Putin’s Economic CounterattackMonkeypox is Spreading Fast. Now Kids Are Getting It, TooHe bought into the brand as well as El
How far off is The Boeing Company ( NYSE:BA ) from its intrinsic value? Using the most recent financial data, we'll...
Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. ET Friday afternoon. As a result, the Dividend Aristocrat's market capitalization has slipped by a staggering $13.2 billion today. Ahead of the opening bell, AbbVie announced its 2022 second-quarter earnings.
This has been a year to remember for investors in seemingly all the wrong ways. Since the major U.S. indexes hit their respective all-time closing highs between mid-November and the first week of January, the timeless Dow Jones Industrial Average, broad-based S&P 500, and growth-driven Nasdaq Composite (NASDAQINDEX: ^IXIC) have shed as much as 19%, 24%, and 34% of their value. You'll note by the drop in the S&P 500 and Nasdaq that both indexes have entered a bear market.
Pervasive pessimism has brought out investors who see a decent setup for Chinese stocks for the second half of the year.
Shares of Roku (NASDAQ: ROKU) opened sharply lower on Friday after a blistering financial update. Roku's plummet to close out the trading week is fair. The ad market has softened swiftly, even for Roku's connected TV stronghold that should've held up better than other marketing markets.
Each of these five real estate investment trusts (REITs) currently pays a dividend of greater than 5%. For those willing to accept the risks, that’s a better yield than that of the U. S. Government 10-Year Treasury Note. Each REIT trades on the New York Stock Exchange, so plenty of information on these REITs is available from analysts at respected investment firms. Looking for ways to boost your returns? Check out Benzinga's coverage on Alternative Real Estate Investments: Exclusive Offering For
Warren Buffett energy favorite Occidental Petroleum is near a buy point, but earnings are due Tuesday. Check out this week's stocks to watch.
It is now guiding for third-quarter revenue of $15 billion-$16 billion vs. the $18.67 billion consensus. As for full-year 2022, its EPS expectation is now $2.30, down from its prior forecast of $3.60 and the $3.39 consensus. In terms of revenue for the year, Intel now expects $65 billion-$68 billion, down from $76 billion and well below the $74.4 billion consensus.
The U.S. Federal Aviation Administration (FAA) on Friday approved Boeing’s inspection and modification plan to resume deliveries of 787 Dreamliners, two people briefed on the matter told Reuters. The FAA approved Boeing’s proposal that requires specific inspections to verify the condition of the airplane meets requirements and that all work has been completed, a move […]
(Bloomberg) -- Investors should stay wary of US stocks and bonds as inflation remains a threat and recession looms, according to Rebecca Patterson, chief investment strategist at Bridgewater Associates.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekShock July Stock Rally Was a Monster the Fed May Regret SeeingMeet the Russian Architect of Putin’s Economic CounterattackMonkeypox is Spreading Fast. Now Kids Are Getting It, TooThe stock market, which finished
Apple delivered better-than-expected earnings and shares are now up 25% from the June low. Here's how to trade it from here.
(Bloomberg) -- With recession fears mounting—and inflation, the war in Ukraine and the lingering pandemic taking a toll—many tech companies are rethinking their staffing needs, with some of them instituting hiring freezes, rescinding offers and making rounds of layoffs.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekShock July Stock Rally Was a Monster the Fed May Regret SeeingMeet the Russian Architect of Putin’s Economic CounterattackMonkeypox is Spreadin
A slowing economy is slowing ad spending. Long-term investors should use this weakness to pick up winners while they're on sale.
SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.